Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02384460Phase 3Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Role: lead

NCT02014376Phase 2Completed

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Role: lead

NCT02090283Phase 2Terminated

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Role: lead

NCT02670330Phase 3Terminated

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Role: lead

All 4 trials loaded